Literature DB >> 28824257

Long-Term Maintenance of Hematological and Cytogenetic Remission in 5q- Syndrome After Short-Term Administration of Lenalidomide.

Yuka Kawaji1, Hiroto Kaneko2, Takahiro Fujino1, Saeko Kuwahara1,3, Muneo Ohshiro1, Yoshiko Hirakawa1, Toshiki Iwai1, Hitoji Uchiyama1, Junya Kuroda3, Masafumi Taniwaki2,3.   

Abstract

Entities:  

Year:  2016        PMID： 28824257      PMCID： PMC5544649          DOI： 10.1007/s12288-016-0761-0

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


× No keyword cloud information.
  4 in total

1.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

Authors:  Pierre Fenaux; Aristoteles Giagounidis; Dominik Selleslag; Odile Beyne-Rauzy; Ghulam Mufti; Moshe Mittelman; Petra Muus; Peter Te Boekhorst; Guillermo Sanz; Consuelo Del Cañizo; Agnes Guerci-Bresler; Lars Nilsson; Uwe Platzbecker; Michael Lübbert; Bruno Quesnel; Mario Cazzola; Arnold Ganser; David Bowen; Brigitte Schlegelberger; Carlo Aul; Robert Knight; John Francis; Tommy Fu; Eva Hellström-Lindberg
Journal:  Blood       Date:  2011-07-13       Impact factor: 22.113

2.  Distinct haematological disorder with deletion of long arm of no. 5 chromosome.

Authors:  H Van den Berghe; J J Cassiman; G David; J P Fryns; J L Michaux; G Sokal
Journal:  Nature       Date:  1974-10-04       Impact factor: 49.962

Review 3.  Advances in the 5q- syndrome.

Authors:  Jacqueline Boultwood; Andrea Pellagatti; Andrew N J McKenzie; James S Wainscoat
Journal:  Blood       Date:  2010-08-23       Impact factor: 22.113

4.  Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.

Authors:  Aristoteles A N Giagounidis; Sabine Haase; Michael Heinsch; Gudrun Göhring; Brigitte Schlegelberger; Carlo Aul
Journal:  Ann Hematol       Date:  2006-11-17       Impact factor: 3.673
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.